Posted by Michael Wonder on 28 Jul 2020
CADTH publishes final recommendation for a new combination product for HIV infection
24 July 2020 - Cabenuva (cabotegravir and rilpivirine extended release injectable suspensions) is indicated as a complete regimen for the treatment of HIV-1 infection in adults to replace the current anti-retroviral regimen in patients who are virologically stable and suppressed (HIV-1 RNA less than 50 copies/mL).
The CADTH Canadian Drug Expert Committee has recommended that the cabotegravir plus rilpivirine regimen be reimbursed for the treatment of HIV-1 infection in adults who are virologically stable and suppressed, only if certain conditions are met.
One of the conditions is that the cost of cabotegravir plus rilpivirine should not exceed the total drug plan cost of treatment with the least costly alternative regimen reimbursed for the treatment of adults with HIV-1 infection.
